SNCA and Parkinson disease: Inhibition of the α-synuclein kinase c-Abl by nilotinib, an FDA-approved cancer treatment, enhanced clearance of α-synuclein in mice, protected neurons from α-synuclein toxicity and improved motor behaviour in a mouse model of Parkinson's disease (261).